CPP
ALNY icon

Crow Point Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Crow Point Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$206K Buy
+1,800
New +$179K 0.32% 63
2019
Q2 		– Sell
-2,190
Closed -$205K – 123
2019
Q1 		$205K Buy
+2,190
New +$183K 0.03% 111

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Crow Point Partners's ALNY Position: Q4 2019 in Review

Crow Point Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2019: 1,800 shares worth $206K. The stake represents 0.32% of the portfolio and ranks #63 among its holdings. This is a return to the name: Crow Point Partners previously reported a position in ALNY as recently as Q1 2019.

Crow Point Partners first reported a position in ALNY in Q1 2019 and has held it in 2 quarters since. 316 funds tracked by Wall St. Rank hold ALNY as of Q4 2019.

  • Crow Point Partners held 1,800 shares of Alnylam Pharmaceuticals worth $206K as of Q4 2019.
  • Alnylam Pharmaceuticals was a new Crow Point Partners position in Q4 2019.
  • Alnylam Pharmaceuticals made up 0.32% of Crow Point Partners's portfolio in Q4 2019, its #63 holding.
  • Crow Point Partners first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 2 quarters since.
  • 316 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.